Drug Profile
Evocalcet - Mitsubishi Tanabe Pharma Corporation
Alternative Names: Evocalcet; KHK 4580; KHK-7580; MT-4580; ORKEDIALatest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Developer Kyowa Kirin
- Class Antihypercalcaemics; Antithyroids; Naphthalenes; Pyrrolidines; Small molecules
- Mechanism of Action Calcium-sensing receptor agonists; Parathyroid hormone receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Secondary hyperparathyroidism
- Registered Hypercalcaemia
Most Recent Events
- 30 Nov 2023 Registered for Secondary hyperparathyroidism in South Korea (PO)
- 30 Aug 2023 Ministry of Health, Labour and Welfare approves evocalcet (ORKEDIA®) for 4 mg tablets for the treatment of Hypercalcaemia and Secondary hyperparathyroidism in Japan
- 31 Mar 2023 Preregistration for Secondary hyperparathyroidism in South Korea (PO)